Time New York: Sat 15 Dec 19:51 pm  |  Save 15% on H&R Block Online


Galapagos Reports Topline Data From Osteoarthritis Study


Galapagos NV GLPG announced positive top-line data from phase Ib study evaluating its osteoarthritis (“OA”) candidate, GLPG1972. The candidate reduced the level of ARGS neoepitope, a cartilage breakdown biomarker, by more than half in its highest dosage.

Shares of the company have risen 43.1% in the past year, outperforming the industry’s decline of 1.7% in that period.

The phase Ib study evaluated three doses of GLPG1972 versus placebo over a period of four weeks. GLPG1972 reduced level of ARGS neoepitope by 38.4%, 44.9% & 50.4% for low, medium and high dose, respectively, compared to 3.6% for placebo.

GLPG1972 works by targeting ADAMTS-5, a cartilage degrading enzyme.

Meanwhile, Galapagos is working on designing the phase II program to further evaluate the candidate in OA. The study is expected to start by the end of this year.

Apart from GLPG1972, Galapagos is also developing another candidate, filgotinib in Sjogren's syndrome, non-infectious uveitis, ankylosing spondylitis, and psoriatic arthritis. The company has a global collaboration with Gilead Sciences, Inc. GILD for the development and commercialization of filgotinib in inflammatory indications.

Moreover, Galapagos is developing GLPG2222 in cystic fibrosis (“CF”) patients who are on long-term stable treatment with Vertex Pharmaceuticals Incorporated’s VRTX CF drug, Kalydeco. In November last year, Galapagos announced positive top-line data from a phase II study, demonstrating an improvement of 2.2% in lung function compared to baseline.

The company has three CF candidate including GLPG2222, which are being developed in partnership with AbbVie Inc. ABBV.

Galapagos carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.